Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations.

Zhang DY, Dmello C, Chen L, Arrieta VA, Gonzalez-Buendia E, Kane JR, Magnusson LP, Baran A, James CD, Horbinski C, Carpentier A, Desseaux C, Canney M, Muzzio M, Stupp R, Sonabend AM.

Clin Cancer Res. 2019 Dec 12. doi: 10.1158/1078-0432.CCR-19-2182. [Epub ahead of print]

PMID:
31831565
2.

Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children's Oncology Group (ACNS1221).

Lafay-Cousin L, Bouffet E, Strother D, Rudneva V, Hawkins C, Eberhart C, Horbinski C, Heier L, Souweidane M, Williams-Hughes C, Onar-Thomas A, Billups CA, Fouladi M, Northcott P, Robinson G, Gajjar A.

J Clin Oncol. 2019 Nov 27:JCO1900845. doi: 10.1200/JCO.19.00845. [Epub ahead of print]

PMID:
31774708
3.

Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas.

Drumm MR, Dixit KS, Grimm S, Kumthekar P, Lukas RV, Raizer JJ, Stupp R, Chheda MG, Kam KL, McCord M, Sachdev S, Kruser T, Steffens A, Javier R, McCortney K, Horbinski C.

Neuro Oncol. 2019 Nov 10. pii: noz216. doi: 10.1093/neuonc/noz216. [Epub ahead of print]

PMID:
31711239
4.

Immunotherapy Against Gliomas: is the Breakthrough Near?

Lukas RV, Wainwright DA, Horbinski CM, Iwamoto FM, Sonabend AM.

Drugs. 2019 Nov;79(17):1839-1848. doi: 10.1007/s40265-019-01203-z. Review.

PMID:
31598900
5.

Myeloid-Derived Suppressive Cells Promote B cell-Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma.

Lee-Chang C, Rashidi A, Miska J, Zhang P, Pituch KC, Hou D, Xiao T, Fischietti M, Kang SJ, Appin CL, Horbinski C, Platanias LC, Lopez-Rosas A, Han Y, Balyasnikova IV, Lesniak MS.

Cancer Immunol Res. 2019 Dec;7(12):1928-1943. doi: 10.1158/2326-6066.CIR-19-0240. Epub 2019 Sep 17.

PMID:
31530559
6.

SRSF3-Regulated RNA Alternative Splicing Promotes Glioblastoma Tumorigenicity by Affecting Multiple Cellular Processes.

Song X, Wan X, Huang T, Zeng C, Sastry N, Wu B, James CD, Horbinski C, Nakano I, Zhang W, Hu B, Cheng SY.

Cancer Res. 2019 Oct 15;79(20):5288-5301. doi: 10.1158/0008-5472.CAN-19-1504. Epub 2019 Aug 28.

PMID:
31462429
7.

IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma.

Kofuji S, Hirayama A, Eberhardt AO, Kawaguchi R, Sugiura Y, Sampetrean O, Ikeda Y, Warren M, Sakamoto N, Kitahara S, Yoshino H, Yamashita D, Sumita K, Wolfe K, Lange L, Ikeda S, Shimada H, Minami N, Malhotra A, Morioka S, Ban Y, Asano M, Flanary VL, Ramkissoon A, Chow LML, Kiyokawa J, Mashimo T, Lucey G, Mareninov S, Ozawa T, Onishi N, Okumura K, Terakawa J, Daikoku T, Wise-Draper T, Majd N, Kofuji K, Sasaki M, Mori M, Kanemura Y, Smith EP, Anastasiou D, Wakimoto H, Holland EC, Yong WH, Horbinski C, Nakano I, DeBerardinis RJ, Bachoo RM, Mischel PS, Yasui W, Suematsu M, Saya H, Soga T, Grummt I, Bierhoff H, Sasaki AT.

Nat Cell Biol. 2019 Aug;21(8):1003-1014. doi: 10.1038/s41556-019-0363-9. Epub 2019 Aug 1.

PMID:
31371825
8.

Clinical Utility of GlioSeq Next-Generation Sequencing Test in Pediatric and Young Adult Patients With Brain Tumors.

Roy S, Agnihotri S, El Hallani S, Ernst WL, Wald AI, Santana Dos Santos L, Hamilton RL, Horbinski CM, Wadhwani NR, Born DE, Pollack IF, Nikiforov YE, Nikiforova MN.

J Neuropathol Exp Neurol. 2019 Jun 10. doi: 10.1093/jnen/nlz055. [Epub ahead of print]

PMID:
31298284
9.

The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients.

Horbinski C, Ligon KL, Brastianos P, Huse JT, Venere M, Chang S, Buckner J, Cloughesy T, Jenkins RB, Giannini C, Nabors LB, Wen PY, Aldape KJ, Lukas RV, Galanis E, Eberhart CG, Brat DJ, Sarkaria JN.

Neuro Oncol. 2019 Jul 4. pii: noz119. doi: 10.1093/neuonc/noz119. [Epub ahead of print]

PMID:
31276167
10.

Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers.

Unruh D, Zewde M, Buss A, Drumm MR, Tran AN, Scholtens DM, Horbinski C.

Sci Rep. 2019 Jun 20;9(1):8946. doi: 10.1038/s41598-019-45346-1.

11.

Polysomy is associated with poor outcome in 1p19q co-deleted oligodendroglial tumors.

Chen H, Thomas C, Munoz FA, Alexandrescu S, Horbinski CM, Olar A, McGuone D, Camelo-Piragua S, Wang L, Pentsova E, Phillips J, Aldape K, Chen W, Iafrate AJ, Chi AS, Zagzag D, Golfinos JG, Placantonakis DG, Rosenblum M, Ohman-Strickland P, Hameed M, Snuderl M.

Neuro Oncol. 2019 May 29. pii: noz098. doi: 10.1093/neuonc/noz098. [Epub ahead of print]

PMID:
31140557
12.

Rapid Development of an Aneurysm at the Anastomotic Site of a Superficial Temporal Artery to Middle Cerebral Artery Bypass: Case Report and Literature Review.

Potts MB, Horbinski CM, Jahromi BS.

World Neurosurg. 2019 Aug;128:314-319. doi: 10.1016/j.wneu.2019.05.108. Epub 2019 May 21.

PMID:
31125771
13.

Correction: Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes.

Huang T, Garcia R, Qi J, Lulla R, Horbinski C, Behdad A, Wadhwani N, Shilatifard A, James C, Saratsis AM.

Oncotarget. 2019 Apr 12;10(28):2788. doi: 10.18632/oncotarget.26881. eCollection 2019 Apr 12.

14.

Tenascin-C expression contributes to pediatric brainstem glioma tumor phenotype and represents a novel biomarker of disease.

Qi J, Esfahani DR, Huang T, Ozark P, Bartom E, Hashizume R, Bonner ER, An S, Horbinski CM, James CD, Saratsis AM.

Acta Neuropathol Commun. 2019 May 15;7(1):75. doi: 10.1186/s40478-019-0727-1.

15.

Systemic and local immunosuppression in patients with high-grade meningiomas.

Li YD, Veliceasa D, Lamano JB, Lamano JB, Kaur G, Biyashev D, Horbinski CM, Kruser TJ, Bloch O.

Cancer Immunol Immunother. 2019 Jun;68(6):999-1009. doi: 10.1007/s00262-019-02342-8. Epub 2019 Apr 27.

PMID:
31030234
16.

Author Correction: Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.

Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A, Filip I, Orenbuch R, Goetz M, Yamaguchi JT, Cloney M, Horbinski C, Lukas RV, Raizer J, Rae AI, Yuan J, Canoll P, Bruce JN, Saenger YM, Sims P, Iwamoto FM, Sonabend AM, Rabadan R.

Nat Med. 2019 Jun;25(6):1022. doi: 10.1038/s41591-019-0449-8.

PMID:
30996326
17.

Long-term glioblastoma survival following recovery from cytomegalovirus colitis: A case report.

Lamano JB, Quaggin-Smith JA, Horbinski CM, Tate MC, Grimm SA, Kumthekar PU, Bloch O.

J Clin Neurosci. 2019 Jun;64:18-21. doi: 10.1016/j.jocn.2019.03.051. Epub 2019 Apr 1.

PMID:
30948314
18.

Interleukin-8/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma.

Hasan T, Caragher SP, Shireman JM, Park CH, Atashi F, Baisiwala S, Lee G, Guo D, Wang JY, Dey M, Wu M, Lesniak MS, Horbinski CM, James CD, Ahmed AU.

Cell Death Dis. 2019 Mar 29;10(4):292. doi: 10.1038/s41419-019-1387-6.

19.

Potent Antineoplastic Effects of Combined PI3Kα-MNK Inhibition in Medulloblastoma.

Eckerdt F, Bell JB, Beauchamp EM, Clymer J, Blyth GT, Kosciuczuk EM, Ma Q, Chen DZ, Horbinski C, Goldman S, Munshi HG, Hashizume R, Platanias LC.

Mol Cancer Res. 2019 Jun;17(6):1305-1315. doi: 10.1158/1541-7786.MCR-18-1193. Epub 2019 Mar 6.

PMID:
30842251
20.

Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.

Lamano JB, Lamano JB, Li YD, DiDomenico JD, Choy W, Veliceasa D, Oyon DE, Fakurnejad S, Ampie L, Kesavabhotla K, Kaur R, Kaur G, Biyashev D, Unruh DJ, Horbinski CM, James CD, Parsa AT, Bloch O.

Clin Cancer Res. 2019 Jun 15;25(12):3643-3657. doi: 10.1158/1078-0432.CCR-18-2402. Epub 2019 Mar 1.

PMID:
30824583
21.

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.

Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A, Filip I, Orenbuch R, Goetz M, Yamaguchi JT, Cloney M, Horbinski C, Lukas RV, Raizer J, Rae AI, Yuan J, Canoll P, Bruce JN, Saenger YM, Sims P, Iwamoto FM, Sonabend AM, Rabadan R.

Nat Med. 2019 Mar;25(3):462-469. doi: 10.1038/s41591-019-0349-y. Epub 2019 Feb 11. Erratum in: Nat Med. 2019 Apr 17;:.

22.

Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017).

Zhai L, Ladomersky E, Lauing KL, Wu M, Scholtens DM, Savoor R, Zhang B, Wu JD, Horbinski C, Lukas RV, Binder DC, Wainwright DA.

Oncoimmunology. 2018 Dec 13;8(3):1548242. doi: 10.1080/2162402X.2018.1548242. eCollection 2019.

23.

Race influences survival in glioblastoma patients with KPS ≥ 80 and associates with genetic markers of retinoic acid metabolism.

Wu M, Miska J, Xiao T, Zhang P, Kane JR, Balyasnikova IV, Chandler JP, Horbinski CM, Lesniak MS.

J Neurooncol. 2019 Apr;142(2):375-384. doi: 10.1007/s11060-019-03110-5. Epub 2019 Jan 31.

PMID:
30706176
24.

Molecular and translational advances in meningiomas.

Suppiah S, Nassiri F, Bi WL, Dunn IF, Hanemann CO, Horbinski CM, Hashizume R, James CD, Mawrin C, Noushmehr H, Perry A, Sahm F, Sloan A, Von Deimling A, Wen PY, Aldape K, Zadeh G; International Consortium on Meningiomas .

Neuro Oncol. 2019 Jan 14;21(Supplement_1):i4-i17. doi: 10.1093/neuonc/noy178.

25.

Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes.

Huang T, Garcia R, Qi J, Lulla R, Horbinski C, Behdad A, Wadhwani N, Shilatifard A, James C, Saratsis AM.

Oncotarget. 2018 Dec 14;9(98):37112-37124. doi: 10.18632/oncotarget.26430. eCollection 2018 Dec 14. Erratum in: Oncotarget. 2019 Apr 12;10(28):2788.

26.

IDH3α regulates one-carbon metabolism in glioblastoma.

May JL, Kouri FM, Hurley LA, Liu J, Tommasini-Ghelfi S, Ji Y, Gao P, Calvert AE, Lee A, Chandel NS, Davuluri RV, Horbinski CM, Locasale JW, Stegh AH.

Sci Adv. 2019 Jan 2;5(1):eaat0456. doi: 10.1126/sciadv.aat0456. eCollection 2019 Jan.

27.

Neuro-surgical considerations for treating IgG4-related disease with rare spinal epidural compression.

Winkel M, Lawton CD, Sanusi OR, Horbinski CM, Dahdaleh NS, Smith ZA.

Surg Neurol Int. 2018 Oct 17;9:209. doi: 10.4103/sni.sni_156_18. eCollection 2018.

28.

Differences in molecular profiles of glioblastomas according to location.

Horbinski C.

Neuro Oncol. 2019 Jan 1;21(1):4-5. doi: 10.1093/neuonc/noy172. No abstract available.

PMID:
30445513
29.

Characterization of Squamous Cell Lung Cancers from Appalachian Kentucky.

Liu J, Murali T, Yu T, Liu C, Sivakumaran TA, Moseley HNB, Zhulin IB, Weiss HL, Durbin EB, Ellingson SR, Liu J, Huang B, Hallahan BJ, Horbinski CM, Hodges K, Napier DL, Bocklage T, Mueller J, Vanderford NL, Fardo DW, Wang C, Arnold SM.

Cancer Epidemiol Biomarkers Prev. 2019 Feb;28(2):348-356. doi: 10.1158/1055-9965.EPI-17-0984. Epub 2018 Oct 30.

PMID:
30377206
30.

Expression of renal cell markers and detection of 3p loss links endolymphatic sac tumor to renal cell carcinoma and warrants careful evaluation to avoid diagnostic pitfalls.

Jester R, Znoyko I, Garnovskaya M, Rozier JN, Kegl R, Patel S, Tran T, Abedalthagafi M, Horbinski CM, Richardson M, Wolff DJ, Lapadat R, Moore W, Rodriguez FJ, Mull J, Olar A.

Acta Neuropathol Commun. 2018 Oct 19;6(1):107. doi: 10.1186/s40478-018-0607-0.

31.

Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas.

Unruh D, Mirkov S, Wray B, Drumm M, Lamano J, Li YD, Haider QF, Javier R, McCortney K, Saratsis A, Scholtens DM, Sarkaria JN, James CD, Horbinski C.

Clin Cancer Res. 2019 Jan 15;25(2):747-759. doi: 10.1158/1078-0432.CCR-18-1222. Epub 2018 Sep 28.

PMID:
30266764
32.

A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human Glioma.

Koehler JW, Miller AD, Miller CR, Porter B, Aldape K, Beck J, Brat D, Cornax I, Corps K, Frank C, Giannini C, Horbinski C, Huse JT, O'Sullivan MG, Rissi DR, Mark Simpson R, Woolard K, Shih JH, Mazcko C, Gilbert MR, LeBlanc AK.

J Neuropathol Exp Neurol. 2018 Nov 1;77(11):1039-1054. doi: 10.1093/jnen/nly085.

33.

Response to BRAF/MEK Inhibition After Progression With BRAF Inhibition in a Patient With Anaplastic Pleomorphic Xanthoastrocytoma.

Hussain F, Horbinski CM, Chmura SJ, Yamini B, Lukas RV.

Neurologist. 2018 Sep;23(5):163-166. doi: 10.1097/NRL.0000000000000194.

PMID:
30169370
34.

An overview of meningiomas.

Buerki RA, Horbinski CM, Kruser T, Horowitz PM, James CD, Lukas RV.

Future Oncol. 2018 Sep;14(21):2161-2177. doi: 10.2217/fon-2018-0006. Epub 2018 Aug 7. Review.

35.

B cell-rich non-neoplastic sentinel lesion preceding primary central nervous system lymphoma.

Javier R, Shaikh N, Lesniak MS, Sonabend A, Stupp R, Behdad A, Horbinski C.

Diagn Pathol. 2018 Jun 5;13(1):37. doi: 10.1186/s13000-018-0717-9.

36.

Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer.

Rosenberg AJ, Wainwright DA, Rademaker A, Galvez C, Genet M, Zhai L, Lauing KL, Mulcahy MF, Hayes JP, Odell DD, Horbinski C, Komanduri S, Tetreault MP, Kim KA, Villaflor VM.

Oncotarget. 2018 May 4;9(34):23482-23493. doi: 10.18632/oncotarget.25235. eCollection 2018 May 4.

37.

A 25-Year-Old Male with a Subgaleal Mass.

Hakar MH, Liu BP, Horbinski CM.

Brain Pathol. 2018 May;28(3):435-436. doi: 10.1111/bpa.12609. No abstract available.

PMID:
29740947
38.

Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system.

Linninger A, Hartung GA, Liu BP, Mirkov S, Tangen K, Lukas RV, Unruh D, James CD, Sarkaria JN, Horbinski C.

Neuro Oncol. 2018 Aug 2;20(9):1197-1206. doi: 10.1093/neuonc/noy051.

39.

Surgical Resection and Adjuvant Radiation Therapy in the Treatment of Skull Base Chordomas.

Sanusi O, Arnaout O, Rahme RJ, Horbinski C, Chandler JP.

World Neurosurg. 2018 Jul;115:e13-e21. doi: 10.1016/j.wneu.2018.02.127. Epub 2018 Mar 12.

PMID:
29545225
40.

MST4 Phosphorylation of ATG4B Regulates Autophagic Activity, Tumorigenicity, and Radioresistance in Glioblastoma.

Huang T, Kim CK, Alvarez AA, Pangeni RP, Wan X, Song X, Shi T, Yang Y, Sastry N, Horbinski CM, Lu S, Stupp R, Kessler JA, Nishikawa R, Nakano I, Sulman EP, Lu X, James CD, Yin XM, Hu B, Cheng SY.

Cancer Cell. 2017 Dec 11;32(6):840-855.e8. doi: 10.1016/j.ccell.2017.11.005.

41.

Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation.

Bell JB, Eckerdt F, Dhruv HD, Finlay D, Peng S, Kim S, Kroczynska B, Beauchamp EM, Alley K, Clymer J, Goldman S, Cheng SY, James CD, Nakano I, Horbinski C, Mazar AP, Vuori K, Kumthekar P, Raizer J, Berens ME, Platanias LC.

Mol Cancer Res. 2018 Jan;16(1):32-46. doi: 10.1158/1541-7786.MCR-17-0397. Epub 2017 Oct 17.

42.

Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival.

Zhai L, Ladomersky E, Lauing KL, Wu M, Genet M, Gritsina G, Győrffy B, Brastianos PK, Binder DC, Sosman JA, Giles FJ, James CD, Horbinski C, Stupp R, Wainwright DA.

Clin Cancer Res. 2017 Nov 1;23(21):6650-6660. doi: 10.1158/1078-0432.CCR-17-0120. Epub 2017 Jul 27.

43.

Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome.

Panwalkar P, Clark J, Ramaswamy V, Hawes D, Yang F, Dunham C, Yip S, Hukin J, Sun Y, Schipper MJ, Chavez L, Margol A, Pekmezci M, Chung C, Banda A, Bayliss JM, Curry SJ, Santi M, Rodriguez FJ, Snuderl M, Karajannis MA, Saratsis AM, Horbinski CM, Carret AS, Wilson B, Johnston D, Lafay-Cousin L, Zelcer S, Eisenstat D, Silva M, Scheinemann K, Jabado N, McNeely PD, Kool M, Pfister SM, Taylor MD, Hawkins C, Korshunov A, Judkins AR, Venneti S.

Acta Neuropathol. 2017 Nov;134(5):705-714. doi: 10.1007/s00401-017-1752-4. Epub 2017 Jul 21.

44.

Transcription elongation factors represent in vivo cancer dependencies in glioblastoma.

Miller TE, Liau BB, Wallace LC, Morton AR, Xie Q, Dixit D, Factor DC, Kim LJY, Morrow JJ, Wu Q, Mack SC, Hubert CG, Gillespie SM, Flavahan WA, Hoffmann T, Thummalapalli R, Hemann MT, Paddison PJ, Horbinski CM, Zuber J, Scacheri PC, Bernstein BE, Tesar PJ, Rich JN.

Nature. 2017 Jul 20;547(7663):355-359. doi: 10.1038/nature23000. Epub 2017 Jul 5.

45.

Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.

Calvert AE, Chalastanis A, Wu Y, Hurley LA, Kouri FM, Bi Y, Kachman M, May JL, Bartom E, Hua Y, Mishra RK, Schiltz GE, Dubrovskyi O, Mazar AP, Peter ME, Zheng H, James CD, Burant CF, Chandel NS, Davuluri RV, Horbinski C, Stegh AH.

Cell Rep. 2017 May 30;19(9):1858-1873. doi: 10.1016/j.celrep.2017.05.014.

46.

Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.

Huang TY, Piunti A, Lulla RR, Qi J, Horbinski CM, Tomita T, James CD, Shilatifard A, Saratsis AM.

Acta Neuropathol Commun. 2017 Apr 17;5(1):28. doi: 10.1186/s40478-017-0436-6.

47.

Mutant IDH1 and seizures in patients with glioma.

Chen H, Judkins J, Thomas C, Wu M, Khoury L, Benjamin CG, Pacione D, Golfinos JG, Kumthekar P, Ghamsari F, Chen L, Lein P, Chetkovich DM, Snuderl M, Horbinski C.

Neurology. 2017 May 9;88(19):1805-1813. doi: 10.1212/WNL.0000000000003911. Epub 2017 Apr 12.

48.

Risk factors for the treatment outcome of retreated pulmonary tuberculosis patients in China: an optimized prediction model.

Wang XM, Yin SH, Du J, Du ML, Wang PY, Wu J, Horbinski CM, Wu MJ, Zheng HQ, Xu XQ, Shu W, Zhang YJ.

Epidemiol Infect. 2017 Jul;145(9):1805-1814. doi: 10.1017/S0950268817000656. Epub 2017 Apr 11.

PMID:
28397611
49.

Therapeutic Hypothesis Testing With Rodent Brain Tumor Models.

Wainwright DA, Horbinski CM, Hashizume R, James CD.

Neurotherapeutics. 2017 Apr;14(2):385-392. doi: 10.1007/s13311-017-0523-1. Review.

50.

Incidence of CNS tumors in Appalachian children.

Huang B, Luo A, Durbin EB, Lycan E, Tucker T, Chen Q, Horbinski C, Villano JL.

J Neurooncol. 2017 May;132(3):507-512. doi: 10.1007/s11060-017-2403-2. Epub 2017 Mar 11.

Supplemental Content

Loading ...
Support Center